A Randomized, Double-Blind, Placebo-Controlled, Multiple Continuous Intravenous Injection, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of M201-A in Healthy Japanese Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs M201-A (Primary)
- Indications Atrial fibrillation; Paroxysmal atrial fibrillation
- Focus Adverse reactions
- 29 Aug 2021 Status changed from recruiting to completed.
- 16 Jul 2020 New trial record